Edition:
United Kingdom

People: Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

11.69USD
21 Sep 2018
Change (% chg)

-- (--)
Prev Close
$11.69
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
52,573
52-wk High
$23.67
52-wk Low
$8.76

Lowinger, Timothy 

Dr. Timothy B. Lowinger, Ph.D., is the Chief Scientific Officer of Mersana Therapeutics, Inc. Dr. Lowinger bringing nearly 15 years of global scientific leadership and drug discovery experience in the pharmaceutical and biotech industries. Over the course of his career at Bayer Pharmaceuticals in the US, Japan and Germany, he contributed to the discovery of more than 15 preclinical and clinical drug candidates in the areas of oncology, asthma, inflammation, virology, obesity and diabetes. Most notably, Dr. Lowinger is a co-inventor of the pioneering anti-angiogenic agent Nexavar (sorafenib), approved for the treatment of renal and hepatocellular cancer, as well as Stivarga (regorafenib), approved for the treatment of metastatic colorectal cancer. Dr. Lowinger has published more than 40 scientific papers and is a co-inventor on more than 40 patents. He has a B.Sc. (Hons.) in Chemistry and a Ph.D. in Organic Chemistry from the University of British Columbia and was a Merck Postdoctoral Fellow at the Ohio State University in the lab of Professor Leo A. Paquette. He currently serves on the Scientific Advisory Board of Keystone Symposia.

Basic Compensation

Total Annual Compensation, USD 370,162
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 147,803
Fiscal Year Total, USD 517,965

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --